Laborecom Therapeutics is a Chicago-based biotech developing LBRC-101, a first-in-class peptide therapeutic that to prevent reperfusion injury following heart attack by blocking the process that immune cells use to enter muscle and cause damage following reperfusion with procedures such as percutaneous coronary intervention (PCI).

LBRC-101 has received NIH SBIR Phase I funding, validating the underlying biology of the LBRC pathway